BeiGene USA News and Activities

BeiGene USA is owned by BeOne Medicines.

BeOne Medicines is one of the...

• CSI 500;
• Forbes Global 2000 (#1847);
• TOB Iconic 10,000.

BeOne Medicines is a company listed under the stock ticker 688235 (HK).

BeOne Medicines has a direct presence in 2 countries.

They are in:

• Biotechnology67%
• Pharmaceuticals33%

Acquisition, funding and merger involving BeOne Medicines.

• BeOne Medicines has just announced a $885 Million fundraising (posted on August 28 2025).
• BeiGene will change its company name to BeOne Medicines. (posted on November 15 2024).

View the org chart displaying its 11 main executives

Most searched biographies at BeiGene USA

• Mark Riedl, Vice President, Sales
• Clare Fisher, Senior Vice President, Business Development and M&A
• Nicole Palmer, Director, Clinical Business Operations

Create your alert
to follow the executive moves at BeiGene USA.

BeOne Medicines has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by BeiGene USA

Social media about BeiGene USA

• BeiGene USA on Wikipedia, Google News & Yahoo Finance
• BeiGene USA on LinkedIn, X (Twitter) & YouTube